We treated seven patients who had progressive hairy-cell leukemia with daily doses of 3 million units of partially pure alpha (leukocyte) interferon by the intramuscular route. Three patients had a complete remission, and four had a partial remission, according to strict criteria for a response. After treatment, bone-marrow aspirates showed an absence of leukemia cells in three patients and 5 per cent or fewer in three others. Normalization of subnormal peripheral-blood values occurred in six of six patients with anemia, in seven of seven with granulocytopenia, and in four of four with thrombocytopenia. Remissions have been maintained for over 6 to over 10 months. Alpha interferon appears to be highly effective in patients with hairy-cell leukemia.
This article has been cited by other articles:
Golomb, H. M.
(2008). Hairy Cell Leukemia: Treatment Successes in the Past 25 Years. JCO
26: 2607-2609
[Full Text]
Braiteh, F., Kurzrock, R.
(2007). Uncommon tumors and exceptional therapies: paradox or paradigm?. Molecular Cancer Therapeutics
6: 1175-1179
[Abstract][Full Text]
Wanko, S. O., de Castro, C.
(2006). Hairy Cell Leukemia: An Elusive but Treatable Disease. The Oncologist
11: 780-789
[Abstract][Full Text]
Ravandi, F., Jorgensen, J. L., O'Brien, S. M., Verstovsek, S., Koller, C. A., Faderl, S., Giles, F. J., Ferrajoli, A., Wierda, W. G., Odinga, S., Huang, X., Thomas, D. A., Freireich, E. J., Jones, D., Keating, M. J., Kantarjian, H. M.
(2006). Eradication of minimal residual disease in hairy cell leukemia. Blood
107: 4658-4662
[Abstract][Full Text]
Ravandi, F., O'Brien, S.
(2005). Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin. Proc.
80: 1660-1674
[Abstract]
Thomas, D. A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M. J., Giles, F. J., Cortes, J., Kantarjian, H. M.
(2003). Rituximab in relapsed or refractory hairy cell leukemia. Blood
102: 3906-3911
[Abstract][Full Text]
Davis, I. D., Jefford, M., Parente, P., Cebon, J.
(2003). Rational approaches to human cancer immunotherapy. J. Leukoc. Biol.
73: 3-29
[Abstract][Full Text]
Federico, M., Zinzani, P. L., Frassoldati, A., Vinceti, M., Mode, A., Annino, L., Chisesi, T., Pagnucco, G., Invernizzi, R., Spriano, M., Resegotti, L., Bendandi, M., Damasio, E. E.
(2002). Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. JCO
20: 638-646
[Abstract][Full Text]
Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I.
(2001). Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. NEJM
345: 241-247
[Abstract][Full Text]
Jonasch, E., Haluska, F. G.
(2001). Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. The Oncologist
6: 34-55
[Abstract][Full Text]
Flinn, I. W., Kopecky, K. J., Foucar, M. K., Head, D., Bennett, J. M., Hutchison, R., Corbett, W., Cassileth, P., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B., Grever, M. R.
(2000). Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood
96: 2981-2986
[Abstract][Full Text]
Shehata, M., Schwarzmeier, J. D., Nguyen, S. T., Hilgarth, M., Berger, R., Hubmann, R., Kickmaier, S., Decker, T.
(2000). Reconstitution of Endogenous Interferon {{alpha}} by Recombinant Interferon in Hairy Cell Leukemia. Cancer Res.
60: 5420-5426
[Abstract][Full Text]
Au, W. Y., Klasa, R. J., Gallagher, R., Le, N., Gascoyne, R. D., Connors, J. M.
(1998). Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience. Blood
92: 1160-1164
[Abstract][Full Text]
Lauria, F., Bocchia, M., Marotta, G., Raspadori, D., Zinzani, P., Rondelli, D.
(1997). Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications. Blood
89: 1838-1839
[Full Text]
Binder, D., Fehr, J., Hengartner, H., Zinkernagel, R. M.
(1997). Virus-induced Transient Bone Marrow Aplasia: Major Role of Interferon-alpha /beta during Acute Infection with the Noncytopathic Lymphocytic Choriomeningitis Virus. JEM
185: 517-530
[Abstract][Full Text]
Gianni, M., Terao, M., Fortino, I., LiCalzi, M., Viggiano, V., Barbui, T., Rambaldi, A., Garattini, E.
(1997). Stat1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells. Blood
89: 1001-1012
[Abstract][Full Text]
Muller, U, Steinhoff, U, Reis, L., Hemmi, S, Pavlovic, J, Zinkernagel, R., Aguet, M
(1994). Functional role of type I and type II interferons in antiviral defense. Science
264: 1918-1921
[Abstract]
Coon, W. W.
(1988). Splenectomy for Thrombocytopenia due to Secondary Hypersplenism. Arch Surg
123: 369-371
[Abstract]
Yap, W., Teo, T., Tan, Y.
(1986). An early event in the interferon-induced transmembrane signaling process. Science
234: 355-358
[Abstract]
Previous
